BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 20082274)

  • 21. Clinical Evaluation of Serum Tumor Markers in the Diagnosis of Gastric Adenocarcinoma Staging and Grading.
    Ghaderi B; Moghbel H; Daneshkhah N; Babahajian A; Sheikhesmaeili F
    J Gastrointest Cancer; 2019 Sep; 50(3):525-529. PubMed ID: 29806060
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum carcinoembryonic antigen as a prognostic factor in resectable gastric cancer.
    Tachibana M; Takemoto Y; Nakashima Y; Kinugasa S; Kotoh T; Dhar DK; Kohno H; Nagasue N
    J Am Coll Surg; 1998 Jul; 187(1):64-8. PubMed ID: 9660027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence.
    Lai IR; Lee WJ; Huang MT; Lin HH
    Hepatogastroenterology; 2002; 49(46):1157-60. PubMed ID: 12143226
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preoperative Tumor Markers Independently Predict Survival in Stage III Gastric Cancer Patients: Should We Include Tumor Markers in AJCC Staging?
    Lin JX; Wang W; Lin JP; Xie JW; Wang JB; Lu J; Chen QY; Cao LL; Lin M; Tu R; Zheng CH; Huang CM; Zhou ZW; Li P
    Ann Surg Oncol; 2018 Sep; 25(9):2703-2712. PubMed ID: 29971670
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Stomach adenocarcinomas: comparison between CA 19-9 and carcinoembryonic antigen for the diagnosis of recurrences after surgical treatment].
    Ychou M; Tuszinski T; Pignon JP; Bidart JM; Bellet D; Bohuon C; Rougier P
    Gastroenterol Clin Biol; 1992; 16(11):848-52. PubMed ID: 1483553
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical utility of CEA, CA 19-9, and CA 72-4 in the follow-up of patients with resectable gastric cancer.
    Marrelli D; Pinto E; De Stefano A; Farnetani M; Garosi L; Roviello F
    Am J Surg; 2001 Jan; 181(1):16-9. PubMed ID: 11248169
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined use of AFP, CEA, CA125 and CAl9-9 improves the sensitivity for the diagnosis of gastric cancer.
    He CZ; Zhang KH; Li Q; Liu XH; Hong Y; Lv NH
    BMC Gastroenterol; 2013 May; 13():87. PubMed ID: 23672279
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the Clinical Significance of Serum Carcinoembryonic Antigen in Patients with Resectable Gastric Adenocarcinoma.
    Dang Y; Ouyang X; Wang K; Zhang F; Huang Q
    Arch Med Res; 2016 Apr; 47(3):196-9. PubMed ID: 27387021
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical evaluation of carcinoembryonic and carbohydrate antigens as cancer biomarkers to monitor palliative chemotherapy in advanced stage gastric cancer.
    Abbas M; Ahmed A; Khan GJ; Baig MMFA; Naveed M; Mikrani R; Cao T; Naeem S; Shi M; Dingding C
    Curr Probl Cancer; 2019 Feb; 43(1):5-17. PubMed ID: 30172422
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary thymic adenocarcinoma with production of carbohydrate antigen 19-9 and carcinoembryonic antigen.
    Misao T; Yamamoto Y; Nakano H; Toyooka S; Yamane M; Satoh K
    Jpn J Thorac Cardiovasc Surg; 2004 Jan; 52(1):30-2. PubMed ID: 14760989
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma?
    Kim YC; Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI; Shin JH
    J Gastroenterol Hepatol; 2009 Dec; 24(12):1869-75. PubMed ID: 19686409
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elevated Pretreatment CEA and CA19-9 Levels are Related to Early Treatment Failure in Esophageal Adenocarcinoma.
    van der Kaaij RT; Voncken FEM; van Dieren JM; Snaebjornsson P; Korse CM; Grootscholten C; Aleman BMP; van Sandick JW
    Am J Clin Oncol; 2019 Apr; 42(4):345-350. PubMed ID: 30724779
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic Value of Preoperative Serum Levels of Five Tumor Markers (Carcinoembryonic Antigen, CA19-9, Alpha-fetoprotein, CA72-4, and CA125) in Gastric Cancer.
    Kim JH; Jun KH; Jung H; Park IS; Chin HM
    Hepatogastroenterology; 2014 May; 61(131):863-9. PubMed ID: 26176088
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preoperative serum carcinoembryonic antigen, carbohydrate antigen19-9 and carbohydrate antigen 125 as prognostic factors for recurrence-free survival in colorectal cancer.
    Yang XQ; Chen C; Wang FB; Peng CW; Li Y
    Asian Pac J Cancer Prev; 2011; 12(5):1251-6. PubMed ID: 21875276
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does serum CA19-9 play a practical role in the management of patients with colorectal cancer?
    Morita S; Nomura T; Fukushima Y; Morimoto T; Hiraoka N; Shibata N
    Dis Colon Rectum; 2004 Feb; 47(2):227-32. PubMed ID: 15043294
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The characteristics of the serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels in gastric cancer cases.
    Wada N; Kurokawa Y; Miyazaki Y; Makino T; Takahashi T; Yamasaki M; Nakajima K; Takiguchi S; Mori M; Doki Y
    Surg Today; 2017 Feb; 47(2):227-232. PubMed ID: 27566604
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictive value of serum CEA, CA19-9 and CA72.4 in early diagnosis of recurrence after radical resection of gastric cancer.
    Li Y; Yang Y; Lu M; Shen L
    Hepatogastroenterology; 2011; 58(112):2166-70. PubMed ID: 22024091
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of CA 72-4, CA 19-9 and CEA in the diagnosis and monitoring of gastric cancer.
    Safi F; Kuhns V; Beger HG
    Int J Biol Markers; 1995; 10(2):100-6. PubMed ID: 7561233
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CA19-9 is a significant prognostic marker of patients with stage III gastric cancer.
    Kambara Y; Miyake H; Nagai H; Yoshioka Y; Shibata K; Asai S; Yuasa N
    Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1918-1924. PubMed ID: 32814681
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of periodic serum CA19-9 test in surveillance after colorectal cancer surgery.
    Okamura R; Hasegawa S; Hida K; Hoshino N; Kawada K; Sugihara K; Sakai Y;
    Int J Clin Oncol; 2017 Feb; 22(1):96-101. PubMed ID: 27503134
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.